Preliminary data from the trial showed that TNX-102 SL did not achieve the primary goal of reducing pain in fibromyalgia patients by at least 30 percent over a three-month period.
Since the drug demonstrated a stronger effect on PTSD patients, the company will now shift their full attention to a late-stage study for this indication.
“We decided that PTSD was the better choice for us,” Seth Lederman, CEO of Tonix, told Reuters. He believes the treatment has potential to achieve a breakthrough therapy status as the Food and Drug Administration has not approved a new PTSD treatment in 15 years.
The company plans to conduct a late-stage study on TNX-102 SL’s ability to treat PTSD in the first quarter of 2017.
More articles on supply chain:
Study prompts formal recommendations for insulin injections
Merck halts development of osteoporosis drug in light of stroke risk
Clinton’s plan to address price hikes on long-standing drugs: 4 points
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
